Cytosorb Therapy in Cardiac Surgery - a Retrospective Study of Hemoadsorption in Patients With Endocarditis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiopulmonary Surgery
- Sponsor
- University Hospital, Basel, Switzerland
- Enrollment
- 249
- Locations
- 1
- Primary Endpoint
- In-Hospital mortality
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients with endocarditis undergoing cardiac surgery with cardio-pulmonary bypass circuit
Exclusion Criteria
- •denial of consent for data use
Outcomes
Primary Outcomes
In-Hospital mortality
Time Frame: during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
In-Hospital mortality (number of deaths) of patients with endocarditis undergoing cardiac surgery and intra-operative CytoSorb haemoadsorption
Secondary Outcomes
- time in intensive care unit (days)(during hospital stay for cardiac surgery from admission until discharge (approximately 15 days))
- In-Hospital time (days)(hospital stay for cardiac surgery from admission until discharge (approximately 15 days))